A new trading day began on Monday, with Compass Therapeutics Inc (NASDAQ: CMPX) stock price down -5.86% from the previous day of trading, before settling in for the closing price of $2.90. CMPX’s price has ranged from $0.76 to $4.08 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -25.56%. With a float of $80.70 million, this company’s outstanding shares have now reached $137.82 million.
Let’s determine the extent of company efficiency that accounts for 35 employees. In terms of profitability, gross margin is 74.8%, operating margin of -1501.0%, and the pretax margin is -1292.88%.
Compass Therapeutics Inc (CMPX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Compass Therapeutics Inc is 41.64%, while institutional ownership is 38.88%.
Compass Therapeutics Inc (CMPX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -25.56% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.43% during the next five years compared to -104.70% drop over the previous five years of trading.
Compass Therapeutics Inc (NASDAQ: CMPX) Trading Performance Indicators
Here are Compass Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 14.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 444.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.47 in one year’s time.
Technical Analysis of Compass Therapeutics Inc (CMPX)
Looking closely at Compass Therapeutics Inc (NASDAQ: CMPX), its last 5-days average volume was 0.76 million, which is a drop from its year-to-date volume of 1.93 million. As of the previous 9 days, the stock’s Stochastic %D was 10.59%. Additionally, its Average True Range was 0.32.
During the past 100 days, Compass Therapeutics Inc’s (CMPX) raw stochastic average was set at 51.96%, which indicates a significant increase from 8.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.59% in the past 14 days, which was lower than the 106.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.54, while its 200-day Moving Average is $1.70. However, in the short run, Compass Therapeutics Inc’s stock first resistance to watch stands at $2.97. Second resistance stands at $3.20. The third major resistance level sits at $3.39. If the price goes on to break the first support level at $2.55, it is likely to go to the next support level at $2.36. Should the price break the second support level, the third support level stands at $2.13.
Compass Therapeutics Inc (NASDAQ: CMPX) Key Stats
With a market capitalization of 377.51 million, the company has a total of 137,589K Shares Outstanding. Currently, annual sales are 850 K while annual income is -42,490 K. The company’s previous quarter sales were 850 K while its latest quarter income was -13,080 K.
